Company profile

Bausch & Lomb Corp

NYSE:BLCOOphthalmic Goods

Drug pipeline (56)

AssetStageRevenueTrialsStatus
Acetic Acidapproved0
Acetylcholine chlorideapproved0
Aluminum acetateapproved0
Atropine sulfateapproved0
BACITRACIN ZINCapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (122)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05360784phase3completed2022-05-132022-11-23Bausch & Lomb Incorporated"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
NCT00198523phase3completed2005-07-012005-10-01Bausch & Lomb IncorporatedA Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
NCT01212471phase3completed2010-09-012011-08-01Bausch & Lomb IncorporatedA Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
NCT00595101phase2completed2007-12-012008-06-01Bausch & Lomb IncorporatedA Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
NCT03489941phase3completed2018-04-072018-04-29Bausch & Lomb IncorporatedA Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

FDA applications (87)

ApplicationTypeApplicantProducts
ANDA 040059ANDABAUSCH AND LOMB PHARMACEUTICALS INC
ANDA 040063ANDABAUSCH AND LOMB PHARMACEUTICALS INC
ANDA 040064ANDABAUSCH AND LOMB INC
ANDA 040065ANDABAUSCH AND LOMB INC
ANDA 040066ANDABAUSCH AND LOMB INC